{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:04:35Z","timestamp":1789398275514,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019832","name":"Gal\u00e1pagos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.amjmed.2022.01.017","type":"journal-article","created":{"date-parts":[[2022,2,5]],"date-time":"2022-02-05T10:12:54Z","timestamp":1644055974000},"page":"879-888.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Biological Disease-Modifying Antirheumatic Drugs and Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis: A Danish Cohort Study"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0482-5563","authenticated-orcid":false,"given":"Shahab","family":"Abtahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-2574","authenticated-orcid":false,"given":"Ren\u00e9","family":"Cordtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-6408","authenticated-orcid":false,"given":"Johanna H M","family":"Driessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M","family":"Burden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.amjmed.2022.01.017_bib0001","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.berh.2007.06.002","article-title":"Comorbidities in rheumatoid arthritis","volume":"21","author":"Michaud","year":"2007","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.017_bib0002","doi-asserted-by":"crossref","first-page":"R154","DOI":"10.1186\/ar3107","article-title":"Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis","volume":"12","author":"Kim","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.amjmed.2022.01.017_bib0003","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.22117","article-title":"Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis","volume":"54","author":"van Staa","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.amjmed.2022.01.017_bib0004","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.1016\/j.amjmed.2022.01.017_bib0005","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00198-016-3769-2","article-title":"Biologic therapies and bone loss in rheumatoid arthritis","volume":"28","author":"Zerbini","year":"2017","journal-title":"Osteoporos Int"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.017_bib0006","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/ard.2007.086348","article-title":"Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis","volume":"68","author":"G\u00fcler-Y\u00fcksel","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.017_bib0007","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/ard.2008.091611","article-title":"Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss","volume":"68","author":"Wijbrandts","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.amjmed.2022.01.017_bib0008","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1136\/ard.2008.106484","article-title":"Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study","volume":"68","author":"Haugeberg","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.amjmed.2022.01.017_bib0009","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/ard.2009.127787","article-title":"Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis","volume":"70","author":"Eekman","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.017_bib0010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/RHU.0b013e3181a5679d","article-title":"Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry","volume":"15","author":"Coulson","year":"2009","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.017_bib0011","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/jbmr.1489","article-title":"Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study","volume":"27","author":"Kim","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.1016\/j.amjmed.2022.01.017_bib0012","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/acr.21937","article-title":"Initiation of tumor necrosis factor \u03b1 antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases","volume":"65","author":"Kawai","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"10.1016\/j.amjmed.2022.01.017_bib0013","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1007\/s00198-013-2321-x","article-title":"Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over","volume":"24","author":"Roussy","year":"2013","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.amjmed.2022.01.017_bib0014","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/CLEP.S99490","article-title":"The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO","volume":"25","author":"Ibfelt","year":"2016","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.amjmed.2022.01.017_bib0015","unstructured":"Statistics Denmark. FOLK2: Population 1. January by sex, age, ancestry, country of origin and citizenship 1980-2021. Available at: https:\/\/www.statbank.dk\/statbank5a\/default.asp?w=1366. Accessed March 19, 2021."},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.017_bib0016","first-page":"263","article-title":"The Danish National Hospital Register. A valuable source of data for modern health sciences","volume":"46","author":"Andersen","year":"1999","journal-title":"Dan Med Bull"},{"issue":"7","key":"10.1016\/j.amjmed.2022.01.017_bib0017","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"17","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.017_bib0018","first-page":"445","article-title":"The Danish prescription registries","volume":"44","author":"Gaist","year":"1997","journal-title":"Dan Med Bull"},{"issue":"9","key":"10.1016\/j.amjmed.2022.01.017_bib0019","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2147\/CLEP.S141438","article-title":"Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry","volume":"29","author":"Ibfelt","year":"2017","journal-title":"Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.amjmed.2022.01.017_bib0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1080\/14034940310017490","article-title":"The validity of self-reported fractures among Danish female nurses: comparison with fractures registered in the Danish National Hospital Register","volume":"32","author":"Hundrup","year":"2004","journal-title":"Scand J Public Health"},{"issue":"6","key":"10.1016\/j.amjmed.2022.01.017_bib0021","doi-asserted-by":"crossref","first-page":"398","DOI":"10.7326\/M18-3079","article-title":"Graphical depiction of longitudinal study designs in health care databases","volume":"170","author":"Schneeweiss","year":"2019","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.017_bib0022","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/pds.4107","article-title":"Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores","volume":"26","author":"Suissa","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.amjmed.2022.01.017_bib0023","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.amjmed.2022.01.017_bib0024","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.amjmed.2022.01.017_bib0025","series-title":"Summary meeting report, 5-7 May 2004","first-page":"9","year":"2004"},{"issue":"2","key":"10.1016\/j.amjmed.2022.01.017_bib0026","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jclinepi.2014.08.011","article-title":"Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review","volume":"68","author":"Ali","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.amjmed.2022.01.017_bib0027","unstructured":"Parsons LS. Paper 214-26: reducing bias in a propensity score matched-pair sample using greedy matching techniques. Available at: https:\/\/support.sas.com\/resources\/papers\/proceedings\/proceedings\/sugi26\/p214-26.pdf. Accessed March 19, 2021."},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.017_bib0028","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","article-title":"FRAX and the assessment of fracture probability in men and women from the UK","volume":"19","author":"Kanis","year":"2008","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.017_bib0029","first-page":"239","article-title":"Effect of tocilizumab on fatigue and bone mineral density in patients with rheumatoid arthritis","volume":"20","author":"Abu-Shakra","year":"2018","journal-title":"Isr Med Assoc J"},{"issue":"2","key":"10.1016\/j.amjmed.2022.01.017_bib0030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jbspin.2014.10.015","article-title":"The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis","volume":"82","author":"Briot","year":"2015","journal-title":"Joint Bone Spine"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.017_bib0031","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/rheumatology\/ket468","article-title":"The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis","volume":"53","author":"Kume","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.amjmed.2022.01.017_bib0032","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/ard.2005.044198","article-title":"Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NfkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis","volume":"65","author":"Vis","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.017_bib0033","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1186\/ar2219","article-title":"A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab","volume":"9","author":"Marotte","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.amjmed.2022.01.017_bib0034","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/ard.2008.091264","article-title":"Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study","volume":"68","author":"Hoff","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.amjmed.2022.01.017_bib0035","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/acr.22519","article-title":"Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials","volume":"67","author":"Siu","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.017_bib0036","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3899\/jrheum.100089","article-title":"Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis","volume":"38","author":"Wang","year":"2011","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.017_bib0037","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1093\/rheumatology\/keab548","article-title":"Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using CPRD","volume":"61","author":"Abtahi","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.amjmed.2022.01.017_bib0038","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/annrheumdis-2020-218758","article-title":"Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study","volume":"80","author":"Abtahi","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.017_bib0039","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11657-018-0424-x","article-title":"Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study","volume":"13","author":"Amiche","year":"2018","journal-title":"Arch Osteoporos"},{"issue":"6","key":"10.1016\/j.amjmed.2022.01.017_bib0040","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0049-0172(99)80007-9","article-title":"Insufficiency fractures of the tibia and fibula","volume":"28","author":"Alonso-Bartolom\u00e9","year":"1999","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.amjmed.2022.01.017_bib0041","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/annrheumdis-2019-215328","article-title":"Medications associated with fracture risk in patients with rheumatoid arthritis","volume":"78","author":"Ozen","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.amjmed.2022.01.017_bib0042","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.2337\/dc12-0788","article-title":"Metformin and the risk of cancer: time-related biases in observational studies","volume":"35","author":"Suissa","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.017_bib0043","first-page":"213","article-title":"The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate","author":"Hope","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.amjmed.2022.01.017_bib0044","unstructured":"European Medicines Agency: The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (Revision 8). EMA\/95098\/2010. Available at: http:\/\/www.encepp.eu\/standards_and_guidance. Accessed March 19, 2021."}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322000791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322000791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:30:42Z","timestamp":1762079442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934322000791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0002934322000791"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.017","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological Disease-Modifying Antirheumatic Drugs and Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis: A Danish Cohort Study","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}